KRYS$282.01
$283
Chart
Performance
Key Stats
AI KRYS Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyKrystal Biotech demonstrates strong financial health and promising growth within the biotechnology sector, supported by innovative genetic medicine development. While valuation metrics are high, its market position and robust pipeline justify a positive outlook, though current technicals suggest short-term volatility.
Thematic
Krystal Biotech is well-positioned in the growing field of genetic medicine, specifically targeting rare diseases with high unmet needs. The commercialization of VYJUVEK and a promising pipeline of gene therapies align with the thematic trend towards personalized and precision medicine.
Fundamental
Krystal Biotech exhibits strong revenue growth and improving profitability, supported by a healthy balance sheet with ample cash reserves. While P/E ratios are elevated, this is common for growth-stage biotech companies.
Technical
The stock is trading within its 52-week range and shows mixed signals across technical indicators. While long-term moving averages suggest a bullish trend, short-term indicators point to potential near-term volatility.
| Factor | Score |
|---|---|
| Genetic Medicine Advancement | 90 |
| Rare Disease Focus | 85 |
| Biotechnology Innovation | 80 |
| Regulatory Landscape | 70 |
| Commercialization Success | 50 |
| Factor | Score |
|---|---|
| Valuation | 60 |
| Profitability | 95 |
| Growth | 80 |
| Balance Sheet Health | 90 |
| Cash Flow | 85 |
| Factor | Score |
|---|---|
| Trend Analysis | 65 |
| Momentum | 40 |
| Volume Confirmation | 70 |
| Support & Resistance | 75 |
| Short-term Indicators | 50 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Positive EPS Surprises
The company has exceeded earnings per share (EPS) estimates in 4 of the last 6 reported quarters, indicating consistent operational strength and effective earnings management.
Potential Undervaluation
The current Price-to-Sales (P/S) ratio of 16.5 (TTM) is significantly lower than its peak of 85.5 in 2023, and the Price-to-Earnings (P/E) ratio of 40.0 (TTM) suggests potential value if future growth materializes.
Bearish Points (7)
Recent Negative Performance
The stock has experienced a significant decline of 29.8% over the past year, and has also underperformed in shorter-term periods (1M: 5.2%, 6M: -5.7%, YTD: -4.15%), indicating recent investor sentiment headwinds.
High P/S Ratio
The Price-to-Sales (P/S) ratio of 16.5 (TTM) is substantially high, potentially indicating that the stock is overvalued relative to its revenue, especially considering the volatility in past revenue figures.
Calendar
August 2025
4
Next Earnings Date
H: $2.11
A: $1.44
L: $1.11
H: 94.60M
A: 91.96M
L: 89.96M
Profile
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Seasonals
Price Target
207.90 USD
The 39 analysts offering 1 year price forecasts for KRYS have a max estimate of 252.00 and a min estimate of 176.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Major biotechnology company involved in genetic medicines and vaccine development, a broad competitor in the gene therapy space.
Weight: 90
A significant biotechnology company with a focus on discovering, developing, and commercializing medicines, including involvement in genetic diseases like Alpha-1 Antitrypsin Deficiency, a pipeline area for KRYS.
Weight: 88
One of the world's largest biotechnology companies with a broad portfolio and significant R&D capabilities, often seen as a general competitor in the biotech sector.
Weight: 85
A global healthcare company with a strong presence in various therapeutic areas, including innovative medicines, making it a broad competitor in the pharmaceutical space.